Company intelligence / Profile preview

Pyramid Biosciences

Waltham, Massachusetts, United Statesorpha.net ↗

Ownership: Private
Development stage: Phase 1

Overview

Lead oncology program PBI-200 (a highly CNS penetrant next-generation NTRK inhibitor) is in a global Phase I/II clinical trial in patients with NTRK-fusion driven cancers. GQ1010 (Trop-2 targeted ADC) is scheduled to enter first-in-human trials within the next 12 months from April 2023.

Therapeutic areas: OncologyDermatology
Modalities: Small moleculesAntibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

2 assets

PBI-200

Phase 1

Indications: Solid tumors, Primary brain cancer, Metastatic brain cancer

1 more asset in the full pipeline.

Request access →

Partnerships

GeneQuantum HealthcareVoronoi Inc.

Beyond the preview

Go deeper on Pyramid Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pyramid Biosciences.

Explore the full profile